130 related articles for article (PubMed ID: 7903362)
1. Drug dissolution from indomethacin-starch hybrid powders prepared by the dry impact blending method.
Ishizaka T; Honda H; Koishi M
J Pharm Pharmacol; 1993 Sep; 45(9):770-4. PubMed ID: 7903362
[TBL] [Abstract][Full Text] [Related]
2. Preparation of drug-diluent hybrid powders by dry processing.
Ishizaka T; Honda H; Kikuchi Y; Ono K; Katano T; Koishi M
J Pharm Pharmacol; 1989 Jun; 41(6):361-8. PubMed ID: 2570829
[TBL] [Abstract][Full Text] [Related]
3. Use of glancing angle X-ray powder diffractometry to depth-profile phase transformations during dissolution of indomethacin and theophylline tablets.
Debnath S; Predecki P; Suryanarayanan R
Pharm Res; 2004 Jan; 21(1):149-59. PubMed ID: 14984270
[TBL] [Abstract][Full Text] [Related]
4. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
5. Drug agglomeration and dissolution--what is the influence of powder mixing?
Kale K; Hapgood K; Stewart P
Eur J Pharm Biopharm; 2009 May; 72(1):156-64. PubMed ID: 19347972
[TBL] [Abstract][Full Text] [Related]
6. Polymer Nanocoating of Amorphous Drugs for Improving Stability, Dissolution, Powder Flow, and Tabletability: The Case of Chitosan-Coated Indomethacin.
Li Y; Yu J; Hu S; Chen Z; Sacchetti M; Sun CC; Yu L
Mol Pharm; 2019 Mar; 16(3):1305-1311. PubMed ID: 30668120
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
8. Dissolution study of nanocrystal powders of a poorly soluble drug by UV imaging and channel flow methods.
Sarnes A; Østergaard J; Jensen SS; Aaltonen J; Rantanen J; Hirvonen J; Peltonen L
Eur J Pharm Sci; 2013 Nov; 50(3-4):511-9. PubMed ID: 23999036
[TBL] [Abstract][Full Text] [Related]
9. Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability.
Fael H; Demirel AL
Int J Pharm; 2021 May; 600():120448. PubMed ID: 33675920
[TBL] [Abstract][Full Text] [Related]
10. A novel standard sample powder preparation method for quantitative analysis of polymorphs.
Okumura T; Otsuka M
J Pharm Sci; 2005 May; 94(5):1013-23. PubMed ID: 15793799
[TBL] [Abstract][Full Text] [Related]
11. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
12. Novel films for drug delivery via the buccal mucosa using model soluble and insoluble drugs.
Kianfar F; Chowdhry BZ; Antonijevic MD; Boateng JS
Drug Dev Ind Pharm; 2012 Oct; 38(10):1207-20. PubMed ID: 22204701
[TBL] [Abstract][Full Text] [Related]
13. Triboelectrification and dissolution property enhancements of solid dispersions.
Asare-Addo K; Šupuk E; Al-Hamidi H; Owusu-Ware S; Nokhodchi A; Conway BR
Int J Pharm; 2015 May; 485(1-2):306-16. PubMed ID: 25772415
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
15. Drug-excipient interactions resulting from powder mixing. III: Solid state properties and their effect on drug dissolution.
Chowhan ZT; Chi LH
J Pharm Sci; 1986 Jun; 75(6):534-41. PubMed ID: 3735096
[TBL] [Abstract][Full Text] [Related]
16. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
[TBL] [Abstract][Full Text] [Related]
17. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin.
Priemel PA; Grohganz H; Gordon KC; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2012 Sep; 82(1):187-93. PubMed ID: 22683936
[TBL] [Abstract][Full Text] [Related]
18. Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods.
Laaksonen T; Liu P; Rahikkala A; Peltonen L; Kauppinen EI; Hirvonen J; Järvinen K; Raula J
Pharm Res; 2011 Oct; 28(10):2403-11. PubMed ID: 21537875
[TBL] [Abstract][Full Text] [Related]
19. Understanding Dissolution and Crystallization with Imaging: A Surface Point of View.
Novakovic D; Isomäki A; Pleunis B; Fraser-Miller SJ; Peltonen L; Laaksonen T; Strachan CJ
Mol Pharm; 2018 Nov; 15(11):5361-5373. PubMed ID: 30247922
[TBL] [Abstract][Full Text] [Related]
20. Influence of the preparation method on the physicochemical properties of indomethacin and methyl-β-cyclodextrin complexes.
Rudrangi SR; Bhomia R; Trivedi V; Vine GJ; Mitchell JC; Alexander BD; Wicks SR
Int J Pharm; 2015 Feb; 479(2):381-90. PubMed ID: 25579867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
